Overview Lamotrigine 25 mg Chewable Tablets, Fasting Status: Completed Trial end date: 2002-03-01 Target enrollment: Participant gender: Summary The objective of this study is to compare the rate and extent of absorption of lamotrigine 25 mg chewable dispersible tablets (test) versus Lamictal® (reference) administered as 2 x 25 mg chewable dispersible tablets under fasting conditions. Phase: Phase 1 Details Lead Sponsor: Teva Pharmaceuticals USATreatments: AnticonvulsantsLamotrigine